Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: octreotide acetate

Summary for Generic Name: octreotide acetate

Drug Master File Entries: see list13
Suppliers: see list2
Therapeutic Class:Hormonal Agents, Suppressant (Pituitary)
Formulation / Manufacturing:see details

Pharmacology for Ingredient: octreotide acetate

Clinical Trials for: octreotide acetate

Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
Status: Completed Condition: Acromegaly

Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly
Status: Completed Condition: Acromegaly

Ultrasound Guided Sandostatin LAR Injection in Acromegaly
Status: Recruiting Condition: Acromegaly

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
Status: Completed Condition: Peritoneal Neoplasms; Intestinal Obstruction; Carcinomatosis

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
Status: Active, not recruiting Condition: Neuroendocrine Carcinoma

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
Status: Active, not recruiting Condition: Neuroendocrine Carcinoma; Neuroendocrine

Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea
Status: Completed Condition: Chemotherapy-induced Diarrhea

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Status: Completed Condition: Neuroendocrine Carcinoma; Islet Cell Carcinoma

Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Status: Completed Condition: Carcinoid Tumor; Malignant Carcinoid Syndrome

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma
Status: Active, not recruiting Condition: Gastrinoma; Glucagonoma; Insulinoma; Metastatic Gastrointestinal Carcinoid Tumor; Pancreatic Polypeptide Tumor; Paraganglioma; Pulmonary Carcinoid Tumor; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Neuroendocrine Carcinoma of the Skin; Regional Gastrointestinal Carcinoid Tumor; Somatostatinoma; Stage III Neuroendocrine Carcinoma of the Skin; Stage IV Neuroendocrine Carcinoma of the Skin; Thyroid Gland Medullary Carcinoma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eurohlth Intl
octreotide acetate
INJECTABLE;INJECTION076330Apr 8, 2005RXYes<disabled>
Fresenius Kabi Usa
octreotide acetate
INJECTABLE;INJECTION077450Feb 10, 2006RXNo<disabled>
Sagent Pharms
octreotide acetate
INJECTABLE;INJECTION091041Nov 12, 2013RXNo<disabled>
Sun Pharm Inds
octreotide acetate
INJECTABLE;INJECTION077329Mar 4, 2008RXNo<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology